We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-10.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.32B
AUM Growth
+$99.8M
Cap. Flow
+$327M
Cap. Flow %
24.74%
Top 10 Hldgs %
52.92%
Holding
77
New
22
Increased
20
Reduced
12
Closed
19
Avg Time Held
0.6 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$86.8M
2
RAD
Rite Aid Corporation
RAD
+$67.2M
3
PEN icon
Penumbra
PEN
+$63.2M
4
SAGE icon
Sage Therapeutics
SAGE
+$52.5M
5
INCY icon
Incyte
INCY
+$50.3M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$85.4M
2
AGN
Allergan plc
AGN
+$41.5M
3
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$36.3M
4
HCA icon
HCA Healthcare
HCA
+$35.4M
5
ABBV icon
AbbVie
ABBV
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 9.13%
3 Communication Services 1.09%
4 Industrials 1%
5 Technology 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$13.9M 1.05%
1,028,132
-184,760
-15% -$2.5M
2013 Q4
7 quarters
CFMS
27
DELISTED
Conformis, Inc. Common Stock
CFMS
$12.4M 0.94%
+27,554
New +$13.9M
2015 Q3
0 quarters
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.1M 0.84%
+262,892
New +$12.4M
2015 Q3
0 quarters
FATE icon
29
Fate Therapeutics
FATE
$232M
$11.1M 0.84%
2,074,836
+67,390
+3% +$460K
2015 Q2
1 quarter
HNT
30
DELISTED
HEALTH NET INC
HNT
$10.8M 0.82%
179,229
-208,899
-54% -$13.8M
2014 Q3
4 quarters
TNET icon
31
TriNet
TNET
$3.2B
$10.7M 0.81%
+639,186
New +$13.1M
2015 Q3
0 quarters
CASC
32
DELISTED
Cascadian Therapeutics, Inc.
CASC
$9.9M 0.75%
602,498
-91,648
-13% -$1.88M
2015 Q2
1 quarter
PRQR icon
33
ProQR Therapeutics
PRQR
$209M
$9.63M 0.73%
660,816
+144,126
+28% +$2.41M
2014 Q3
4 quarters
BPMC icon
34
DELISTED
Blueprint Medicines
BPMC
$7.84M 0.59%
367,485
-10,750
-3% -$297K
2015 Q2
1 quarter
TRIV
35
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$7.32M 0.55%
1,463,983
-580
-0% -$3.12K
2014 Q2
5 quarters
CERS icon
36
Cerus
CERS
$449M
$7.28M 0.55%
1,603,427
– –
2015 Q1
2 quarters
NGNE icon
37
Neurogene
NGNE
$465M
$7.24M 0.55%
+25,715
New +$5.92M
2015 Q3
0 quarters
ADVM icon
38
DELISTED
Adverum Biotechnologies
ADVM
$6.17M 0.47%
74,842
+21,114
+39% +$2.7M
2014 Q3
4 quarters
RGNX icon
39
Regenxbio
RGNX
$456M
$6.1M 0.46%
+277,000
New +$7.07M
2015 Q3
0 quarters
DRRX icon
40
DELISTED
DURECT Corp
DRRX
$5.1M 0.39%
+261,332
New +$5.94M
2015 Q3
0 quarters
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.99M 0.38%
+590,100
New +$5.44M
2015 Q3
0 quarters
NVTA
42
DELISTED
Invitae Corporation
NVTA
$4.77M 0.36%
660,129
+478,905
+264% +$5.03M
2015 Q1
2 quarters
CSLT
43
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$3.08M 0.23%
734,397
-1,250,234
-63% -$7.89M
2014 Q1
6 quarters
CCXI icon
44
DELISTED
ChemoCentryx, Inc.
CCXI
$3.03M 0.23%
500,615
+24,322
+5% +$176K
2015 Q1
2 quarters
PGND
45
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
$2.51M 0.19%
+84,966
New +$2.59M
2015 Q3
0 quarters
CARM icon
46
DELISTED
Carisma Therapeutics
CARM
$2.04M 0.15%
42,418
-20,645
-33% -$1.27M
2014 Q4
3 quarters
IRWD icon
47
Ironwood Pharmaceuticals
IRWD
$620M
$1.99M 0.15%
+227,802
New +$2.13M
2015 Q3
0 quarters
NVRO icon
48
DELISTED
NEVRO CORP.
NVRO
$1.16M 0.09%
+25,000
New +$1.21M
2015 Q3
0 quarters
GNCA
49
DELISTED
Genocea Biosciences, Inc.
GNCA
$628K 0.05%
11,456
-66,484
-85% -$6.59M
2015 Q1
2 quarters
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$9.83B
$576K 0.04%
+9,250
New +$729K
2015 Q3
0 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2015 Portfolio in Review

As of Q3 2015, Redmile Group held 77 positions worth $1.32B, up 8.2% from $1.22B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group deployed $327M of net new capital in Q3 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $25.7M trimmed.

  • Redmile Group's largest Q3 2015 buy was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
  • Redmile Group added most to Sage Therapeutics in Q3 2015, an estimated $52.5M increase.
  • Redmile Group's biggest Q3 2015 reduction was Jazz Pharmaceuticals, cutting an estimated $25.7M.
  • Redmile Group fully exited Bausch Health in Q3 2015, selling an estimated $85.4M.
  • Redmile Group's ten largest holdings make up 53% of its $1.32B portfolio in Q3 2015.
  • Redmile Group opened 22 new positions and closed 19 in Q3 2015.
  • Redmile Group's portfolio value rose 8.2% quarter-over-quarter to $1.32B.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.